Individual ATG dosing for stem cell transplant from unrelated donors
Part of Infections clinical trials.
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer that can be treated with a stem cell transplant from an unrelated donor.
- Your donor must match your HLA type (a type of tissue matching).
- You must be between 14 and 65 years old.
- Your liver and kidney function must be within certain limits, as shown in blood tests.
- You should be in relatively good health, with no serious infections or mental illness, and a performance status score of 0 to 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.